Gualdani, Roberta
[UCL]
Cavalluzzi, Maria Maddalena
Tadini-Buoninsegni, Francesco
Lentini, Giovanni
The human Ether-a-go-go Related Gene (hERG) potassium channel plays a central role in the rapid component (IKr) of cardiac action potential repolarization phase. A large number of structurally different compounds block hERG and cause a high risk of arrhythmias. Among the drugs that block hERG channel, a few compounds have been identified as hERG channel activators. Such compounds may be useful, at least in theory, for the treatment of long term QT syndrome. Here we describe a new activator of hERG channel, named MC450. This compound is a symmetric urea, derived from (R)-mexiletine. Using patch-clamp recordings, we found that MC450 increased the activation current of hERG channel, with an EC50 of 41 ± 4 μM. Moreover MC450 caused a depolarizing shift in the voltage dependence of inactivation from − 64.1 ± 1.2 mV (control), to − 35.9 ± 1.4 mV, whereas it had no effect on the voltage dependence of activation. Furthermore, MC450 slowed current inactivation and the effect of MC450 was attenuated by the inactivation-impaired double mutant G628C/S631C.
Bibliographic reference |
Gualdani, Roberta ; Cavalluzzi, Maria Maddalena ; Tadini-Buoninsegni, Francesco ; Lentini, Giovanni. Discovery of a new mexiletine-derived agonist of the hERG K + channel. In: Biophysical Chemistry, Vol. 229, no.229, p. 62-67 (2017) |
Permanent URL |
http://hdl.handle.net/2078.1/211397 |